TABLE OF CONTENTS
1 INTRODUCTION 44
1.1 OBJECTIVES OF THE STUDY 44
1.2 MARKET DEFINITION 44
1.3 OVERVIEW OF THE EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET 44
1.4 LIMITATIONS 46
1.5 MARKETS COVERED 46
2 MARKET SEGMENTATION 49
2.1 MARKETS COVERED 49
2.2 GEOGRAPHICAL SCOPE 50
2.3 YEARS CONSIDERED FOR THE STUDY 51
2.4 CURRENCY AND PRICING 51
2.5 DBMR TRIPOD DATA VALIDATION MODEL 52
2.6 MULTIVARIATE MODELLING 55
2.7 PRODUCT TYPE LIFELINE CURVE 55
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 56
2.9 DBMR MARKET POSITION GRID 57
2.10 MARKET END USER COVERAGE GRID 58
2.11 VENDOR SHARE ANALYSIS 59
2.12 SECONDARY SOURCES 60
2.13 ASSUMPTIONS 60
3 EXECUTIVE SUMMARY 61
4 PREMIUM INSIGHTS 64
4.1 PORTERS FIVE FORCES 65
4.2 PESTEL ANALYSIS 66
5 INDUSTRY INSIGHTS: 67
6 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, REGULATIONS 68
6.1 REGULATORY SCENARIO IN THE U.S 68
6.2 REGULATORY SCENARIO IN AUSTRALIA 68
6.3 REGULATORY SCENARIO IN JAPAN 69
6.4 REGULATORY SCENARIO IN CHINA 69
7 MARKET OVERVIEW 71
7.1 DRIVERS 73
7.1.1 GROWING PREVALENCE OF COLORECTAL CANCER 73
7.1.2 RISE IN THE NUMBER OF PATIENTS SUFFERING FROM DIVERTICULITIS AND ULCERATIVE COLITIS. 73
7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 73
7.2 RESTRAINTS 74
7.2.1 STRINGENT REGULATORY POLICIES 74
7.2.2 HIGH COST FOR THE COLORECTAL CANCER TREATMENTS. 74
7.3 OPPORTUNITIES 75
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 75
7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 76
7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 76
7.4 CHALLENGES 77
7.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 77
7.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 78
8 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 79
8.1 OVERVIEW 80
8.2 INSTRUMENTS 83
8.2.1 PATHOLOGY-BASED INSTRUMENTS 84
8.2.1.1 PCR INSTRUMENTS 84
8.2.1.2 SLIDE STAINING SYSTEMS 84
8.2.1.3 TISSUE PROCESSING SYSTEMS 85
8.2.1.4 CELL PROCESSORS 85
8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 85
8.2.2 IMAGING INSTRUMENTS 85
8.2.2.1 ULTRASOUND SYSTEMS 85
8.2.2.2 CT SYSTEMS 85
8.2.2.3 MRI SYSTEMS 86
8.2.2.4 OTHERS 86
8.2.3 BIOPSY INSTRUMENTS 86
8.2.4 OTHERS 86
8.3 CONSUMABLES & ACCESSORIES 86
8.3.1 KITS 87
8.3.1.1 PCR KITS 87
8.3.1.2 DNA POLYMERASE KITS 87
8.3.1.3 NUCLEIC ACID ISOLATION KITS 87
8.3.1.4 OTHERS 88
8.3.2 REAGENTS 88
8.3.2.1 ASSAYS 88
8.3.2.2 BUFFERS 88
8.3.2.3 PRIMERS 88
8.3.2.4 OTHERS 88
8.3.3 OTHER CONSUMABLES 88
9 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE 89
9.1 OVERVIEW 90
9.2 STOOL EXAMINATION 93
9.3 BLOOD TEST 93
9.3.1 COMPLETE BLOOD COUNT (CBC) 94
9.3.2 TUMOR MARKER TEST 95
9.3.3 LIVER ENZYME BLOOD TEST 95
9.4 IMAGING TEST 95
9.4.1 COMPUTED TOMOGRAPHY (CT) SCAN 96
9.4.2 MRI 96
9.4.3 ULTRASOUND 96
9.4.4 POSITION EMISSION TOMOGRAPHY (PET) 97
9.4.5 OTHERS 97
9.5 TUMOR MARKERS 97
9.5.1 CARCINOEMBRYONIC ANTIGEN (CEA) 98
9.5.2 CA19-9 BIOMARKER TEST 98
9.5.3 CA 50 MARKER TEST 98
9.5.4 OTHERS 98
9.6 BIOPSY 98
9.7 OTHERS 99
10 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES 100
10.1 OVERVIEW 101
10.2 STAGE III 104
10.3 STAGE IV 104
10.4 STAGE II 105
10.5 STAGE I 106
10.6 STAGE 0 106
11 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP 108
11.1 OVERVIEW 109
11.2 GERIATRIC 112
11.3 ADULTS 112
11.4 PEDIATRIC 113
12 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 115
12.1 OVERVIEW 116
12.2 ADENOCARCINOMA 119
12.3 COLORECTAL LYMPHOMA 119
12.4 GASTROINTESTINAL STROMAL TUMORS 120
12.5 CARCINOID TUMORS 121
12.6 OTHERS 121
13 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER 123
13.1 OVERVIEW 124
13.2 HOSPITALS 127
13.3 DIAGNOSTIC CENTERS 127
13.4 CANCER RESEARCH CENTERS 128
13.5 AMBULATORY SURGICAL CENTERS 129
13.6 ACADEMIC INSTITUTES 129
13.7 OTHERS 130
14 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION 132
14.1 EUROPE 133
14.1.1 GERMANY 143
14.1.2 FRANCE 148
14.1.3 U.K. 153
14.1.4 ITALY 158
14.1.5 SPAIN 163
14.1.6 RUSSIA 168
14.1.7 TURKEY 173
14.1.8 NETHERLANDS 178
14.1.9 BELGIUM 183
14.1.10 SWITZERLAND 188
14.1.11 REST OF EUROPE 193
15 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 194
15.1 COMPANY SHARE ANALYSIS: EUROPE 194
16 SWOT ANALYSIS 195
17 COMPANY PROFILE 196
17.1 F. HOFFMANN- LA ROCHE LTD 196
17.1.1 COMPANY SNAPSHOT 196
17.1.2 REVENUE ANALYSIS 196
17.1.3 COMPANY SHARE ANALYSIS 197
17.1.4 PRODUCT PORTFOLIO 197
17.1.5 RECENT DEVELOPMENT 197
17.2 KONINKLIJKE PHILIPS N.V. 198
17.2.1 COMPANY SNAPSHOT 198
17.2.2 REVENUE ANALYSIS 198
17.2.3 COMPANY SHARE ANALYSIS 199
17.2.4 PRODUCT PORTFOLIO 199
17.2.5 RECENT DEVELOPMENT 199
17.3 THERMO FISHER SCIENTIFIC INC. 201
17.3.1 COMPANY SNAPSHOT 201
17.3.2 REVENUE ANALYSIS 201
17.3.3 COMPANY SHARE ANALYSIS 202
17.3.4 PRODUCT PORTFOLIO 202
17.3.5 RECENT DEVELOPMENT 202
17.4 ILLUMINA, INC. 203
17.4.1 COMPANY SNAPSHOT 203
17.4.2 REVENUE ANALYSIS 203
17.4.3 COMPANY SHARE ANALYSIS 204
17.4.4 PRODUCT PORTFOLIO 204
17.4.5 RECENT DEVELOPMENT 204
17.5 QUEST DIAGNOSTICS INCORPORATED 205
17.5.1 COMPANY SNAPSHOT 205
17.5.2 REVENUE ANALYSIS 205
17.5.3 COMPANY SHARE ANALYSIS 206
17.5.4 PRODUCT PORTFOLIO 206
17.5.5 RECENT DEVELOPMENT 206
17.6 ABBOTT 207
17.6.1 COMPANY SNAPSHOT 207
17.6.2 REVENUE ANALYSIS 207
17.6.3 PRODUCT PORTFOLIO 208
17.6.4 RECENT DEVELOPMENT 208
17.7 AGILENT TECHNOLOGIES, INC. 209
17.7.1 COMPANY SNAPSHOT 209
17.7.2 REVENUE ANALYSIS 209
17.7.3 PRODUCT PORTFOLIO 210
17.7.4 RECENT DEVELOPMENT 210
17.8 BD 211
17.8.1 COMPANY SNAPSHOT 211
17.8.2 REVENUE ANALYSIS 211
17.8.3 PRODUCT PORTFOLIO 212
17.8.4 RECENT DEVELOPMENT 212
17.9 BEIJING O&D BIOTECH CO., LTD. 213
17.9.1 COMPANY SNAPSHOT 213
17.9.2 PRODUCT PORTFOLIO 213
17.9.3 RECENT DEVELOPMENT 213
17.10 BIOFIRE DIAGNOSTICS 214
17.10.1 COMPANY SNAPSHOT 214
17.10.2 REVENUE ANALYSIS 214
17.10.3 PRODUCT PORTFOLIO 215
17.10.4 RECENT DEVELOPMENT 215
17.11 BIO-RAD LABORATORIES, INC. 216
17.11.1 COMPANY SNAPSHOT 216
17.11.2 REVENUE ANALYSIS 216
17.11.3 PRODUCT PORTFOLIO 217
17.11.4 RECENT DEVELOPMENT 217
17.12 CANON MEDICAL SYSTEMS CORPORATION. 218
17.12.1 COMPANY SNAPSHOT 218
17.12.2 REVENUE ANALYSIS 218
17.12.3 PRODUCT PORTFOLIO 219
17.12.4 RECENT DEVELOPMENT 219
17.13 FONAR CORP. 220
17.13.1 COMPANY SNAPSHOT 220
17.13.2 REVENUE ANALYSIS 220
17.13.3 PRODUCT PORTFOLIO 221
17.13.4 RECENT DEVELOPMENT 221
17.14 FUJIFILM CORPORATION 222
17.14.1 COMPANY SNAPSHOT 222
17.14.2 REVENUE ANALYSIS 222
17.14.3 PRODUCT PORTFOLIO 223
17.14.4 RECENT DEVELOPMENT 223
17.15 GE HEALTHCARE. 224
17.15.1 COMPANY SNAPSHOT 224
17.15.2 REVENUE ANALYSIS 224
17.15.3 PRODUCT PORTFOLIO 225
17.15.4 RECENT DEVELOPMENT 225
17.16 HOLOGIC, INC. 226
17.16.1 COMPANY SNAPSHOT 226
17.16.2 REVENUE ANALYSIS 226
17.16.3 PRODUCT PORTFOLIO 227
17.16.4 RECENT DEVELOPMENT 227
17.17 MEDONICA CO. LTD 228
17.17.1 COMPANY SNAPSHOT 228
17.17.2 PRODUCT PORTFOLIO 228
17.17.3 RECENT DEVELOPMENT 228
17.18 MERCK KGAA 229
17.18.1 COMPANY SNAPSHOT 229
17.18.2 REVENUE ANALYSIS 229
17.18.3 PRODUCT PORTFOLIO 230
17.18.4 RECENT DEVELOPMENT 230
17.19 MINFOUND MEDICAL SYSTEMS CO., LTD 231
17.19.1 COMPANY SNAPSHOT 231
17.19.2 PRODUCT PORTFOLIO 231
17.19.3 RECENT DEVELOPMENT 231
17.20 MYRIAD GENETICS, INC. 232
17.20.1 COMPANY SNAPSHOT 232
17.20.2 REVENUE ANALYSIS 232
17.20.3 PRODUCT PORTFOLIO 233
17.20.4 RECENT DEVELOPMENT 233
17.21 NEUSOFT CORPORATION 234
17.21.1 COMPANY SNAPSHOT 234
17.21.2 REVENUE ANALYSIS 234
17.21.3 PRODUCT PORTFOLIO 235
17.21.4 RECENT DEVELOPMENT 235
17.22 PLEXBIO 236
17.22.1 COMPANY SNAPSHOT 236
17.22.2 PRODUCT PORTFOLIO 236
17.22.3 RECENT DEVELOPMENT 236

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.